Avalyn Pharma
About Avalyn Pharma
Avalyn Pharma is a clinical-stage biotechnology company focused on developing inhaled therapies to treat rare respiratory diseases. Their work centers on delivering targeted treatments directly to the lungs, with a focus on conditions such as pulmonary fibrosis. The company operates in the biotech and healthcare research space, advancing novel inhalation approaches from discovery through early clinical development. Based in the United States, Avalyn Pharma aims to improve outcomes for patients with hard-to-treat rare lung diseases through scientific innovation and translational science.
Recent News
Seaport, Hemab Price IPOs, While Avalyn Soars in Nasdaq Debut
Fibrosis Company Avalyn Seeks NASDAQ Listing Amid Volatility: Finance Report
Avalyn Pharma (AVLN) IPO Deck
Biotech’s IPO Tide Is Finally Turning, Thanks in Part to the Recent M&A Surge
Avalyn Plots $182M IPO; WHO Prequalifies Novartis' Malaria Drug
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Avalyn Pharma Prices $300 Million IPO at $18 per Share, Expanding Biotech B2B Financing
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
US Biopharma Company Avalyn Pharma Hires Freshfields’ Global Head of Life Sciences as GC